During the last decade, several new TRT formulations have been introduced on the market, including oral, transdermal, and parenteral formulations. Possible advantages and limitations have been discussed appropriately. Anti-estrogens, including selective estrogen modulators or aromatase inhibitors still represent further possible off-label options. However, long-term side effects on sexual function and bone parameters constitute major limitations. Glucagon-like peptide 1 analogues can be an alternative option in particular for massive obesity-associated TD. Weight loss obtained through lifestyle modifications including diet and physical exercise should be encouraged in all overweight and obese patients. A combination of TRT and lifestyle changes can be considered in those subjects in whom a reversal of the condition cannot be expected in a reasonable time frame.
Keyphrases
- weight loss
- bariatric surgery
- obese patients
- roux en y gastric bypass
- gastric bypass
- replacement therapy
- small molecule
- weight gain
- bone mineral density
- glycemic control
- health insurance
- estrogen receptor
- metabolic syndrome
- soft tissue
- molecular docking
- physical activity
- cardiovascular disease
- type diabetes
- body composition
- body mass index
- postmenopausal women
- bone regeneration
- adipose tissue
- high fat diet induced